SCHEMBL20205097

SCHEMBL20205097

CC(C)(C)CNc1nccc(C(=O)Nc2cnc(F)cc2N2CCOCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 9/20 0.46
GSK3A P49840 2/20 0.45
GSK3B P49841 2/20 0.45
HRH4 Q9H3N8 3/20 0.42
MAPK1 P28482 2/20 0.42
HRH3 Q9Y5N1 2/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
TTK P33981 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20204972 0.83 TSHR (0.51) IRAK4GSK3AGSK3BMAPK1TSHR
SCHEMBL29939856 0.83 TSHR (0.51) IRAK4GSK3AGSK3BMAPK1TSHR
SCHEMBL20204946 0.82 IRAK4 (0.45) IRAK4GSK3AGSK3BMAPK1TSHR
SCHEMBL29938993 0.82 IRAK4 (0.45) IRAK4GSK3AGSK3BMAPK1TSHR
SCHEMBL20204994 0.81 GSK3A (0.54) GSK3AGSK3BMAPK1TSHRALOX15
SCHEMBL20205194 0.80 KIF18A (0.43) IRAK4GSK3AGSK3BHRH4MAPK1
SCHEMBL20205173 0.80 MAPK1 (0.52) IRAK4GSK3AGSK3BMAPK1TSHR
SCHEMBL29939117 0.80 MAPK1 (0.52) IRAK4GSK3AGSK3BMAPK1TSHR
SCHEMBL20205219 0.79 GSK3A (0.49) GSK3AGSK3BMAPK1TSHRALOX15
SCHEMBL29939489 0.79 GSK3A (0.49) GSK3AGSK3BMAPK1TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3544613-B1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-09 EP disclosed
US-10752609-B2 GSK-3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-25 US disclosed
US-20190315714-A1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
WO-2018098412-A1 GSK-3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315714-A1 GSK-3 INHIBITORS GSK3B, GSK3A, GSKIP IRAK4 2983/4885GSK3A 2/4885GSK3B 1/4885
US-10752609-B2 GSK-3 inhibitors GSK3B, GSK3A, GSKIP IRAK4 2983/4885GSK3A 2/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.